Leerink Partners Maintains Outperform on Medtronic, Lowers Price Target to $104

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Leerink Partners analyst Mike Kratky maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $117 to $104.